Innovent Dosed First Participant in Phase 3 Clinical Study (

Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity

Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity

sina.com.hk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.hk Daily Mail and Mail on Sunday newspapers.

Related Keywords

China , Hong Kong , Macau , United States , Peking , Beijing , Suzhou , Jiangsu , Taiwan , Chinese , Eli Lilly , Adimab Incyte , Linong Ji , Innovent Biologics , University People Hospital , Innovent Biologics Inc , Md Anderson Cancer Center , Global Health Data Exchange , Incyte Corporation , Company Lilly , Clinical Development At Innovent , Institute For Health Metrics , Innovent Rd Code , Peking University People , Lei Qian , Vice President , Clinical Development , Sintilimab Injection , Bevacizumab Injection , Adalimumab Injection , Rituximab Injection , Pemigatinib Oral Inhibitor , Ramucirumab Injection , Selpercatinib Capsules , Autoleucel Injection , Tafolecimab Injection , Cancer Center , Mainland China , Lancet Diabetes Endocrinol , Health Metrics , Global Health Data ,